Monday, July 15, 2024

Retinal Vein Occlusion Treatment Advances with Positive CHMP Opinion for Roche’s Vabysmo

Similar articles

Roche’s Vabysmo (faricimab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for treating visual impairment due to macular edema secondary to retinal vein occlusion (RVO). This recommendation, based on robust data from two Phase III studies, paves the way for the first bispecific antibody treatment for nearly one million people with RVO in the European Union.

RVO, the second leading cause of vision loss due to retinal vascular diseases, affects approximately 28 million adults globally, primarily those over 60. It leads to sudden vision loss due to vein blockages in the retina, causing macular edema, ischemia, bleeding, and fluid leakage. These conditions can severely impact the quality of life, leading to difficulty in performing daily activities, loss of independence, and increased risk of depression.

The Phase III BALATON and COMINO studies involved over 1,200 participants with branch and central retinal vein occlusion. These studies demonstrated that Vabysmo provided early and sustained vision improvements comparable to aflibercept, a current standard treatment. The results showed significant retinal drying and consistent safety profiles over 72 weeks. Vabysmo’s unique mechanism of action, targeting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), helps stabilize blood vessels and reduce inflammation, which are critical factors in managing RVO. Dr. Levi Garraway, Roche’s Chief Medical Officer, emphasized that this development marks a crucial step in offering new treatment options for patients with vision loss due to retinal vein occlusion.

Vabysmo’s Approval for Retinal Vein Occlusion to Address Unmet Medical Need and Expand in Europe

Levi Garraway noted that Vabysmo’s approval would address a significant unmet medical need by preserving and enhancing vision for many affected individuals, potentially reducing the frequency of injections required compared to current treatments. Vabysmo was first approved for RVO in the United States in October 2023 and in Japan in March 2024. It is also authorized in over 95 countries for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The European Commission’s final decision on Vabysmo’s approval for retinal vein occlusion is anticipated soon, potentially expanding its availability to European patients.

The positive CHMP recommendation is a testament to the rigorous clinical evaluation and substantial evidence supporting Vabysmo’s efficacy and safety. The approval process in different regions reflects the global burden of RVO and the urgent need for innovative therapies. Vabysmo’s ability to provide sustained vision improvement and its favorable safety profile make it a promising option for patients and healthcare providers alike.

Roche’s extensive retina pipeline underscores its commitment to addressing the leading causes of vision loss through innovative treatments. By leveraging scientific advancements and patient insights, Roche aims to develop therapies that significantly improve patients’ quality of life. The company’s ongoing Phase III and IV studies continue to explore Vabysmo’s efficacy and safety in various retinal conditions, ensuring comprehensive treatment options.

Retinal Vein Occlusion

Transforming Retinal Vein Occlusion Treatment with Pioneering Research

Roche’s approach to ophthalmology is driven by a deep understanding of the biological mechanisms underlying retinal diseases and a dedication to pioneering research. This includes exploring gene therapies, personalized medicine, and advanced drug delivery systems. The company’s efforts are aimed at not only treating but potentially curing certain retinal conditions, transforming the standard of care, and offering hope to millions of patients worldwide. If approved, Vabysmo will be a pioneering treatment for retinal vein occlusion, offering patients in the European Union a new, effective therapy to manage their condition.

This milestone aligns with Roche’s mission to transform healthcare and improve patient outcomes through cutting-edge medical solutions. The potential approval of Vabysmo for RVO in Europe could set a new standard in the treatment landscape, providing a much-needed option for patients who have limited choices. The broader implications of Vabysmo’s approval extend beyond just retinal vein occlusion. As Roche continues to innovate in the field of ophthalmology, the success of Vabysmo could pave the way for future therapies targeting other complex retinal diseases. This reinforces Roche’s leadership in the market and its commitment to bringing transformative treatments to patients around the globe.

You can follow our news on our Telegram and LinkedIn accounts.

Roche’s Vabysmo represents a significant advancement in the treatment of retinal vein occlusion. The positive CHMP recommends patients suffering to highlight the drug’s potential to address a critical unmet need in ophthalmology. With its unique mechanism of action, robust clinical data, and global approval status, Vabysmo is poised to become a cornerstone in the management of retinal vein occlusion. This development underscores Roche’s dedication to improving vision health and enhancing the lives of patientssuffering from vision loss due to retinal diseases.


Resource: Roche, June 28, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article